Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
TxCell SA (TXCL FP)
Watchlist
5
Analysis
Health Care
•
France
TxCell SA researches and develops biotechnological products. The Company offers cell-based immunotherapies for the treatment of chronic inflammatory, bowel, joint, and neurological diseases.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
TxCell SA
•
22 Feb 2018 16:51
•
Issuer-paid
TxCell - Robust and stable Treg manufacturing
TxCell has disclosed that it has a viable manufacturing route for its novel CAR Treg products. This uses a stable but low-frequency Treg cell type....
Edison Investment Research
Follow
96 Views
Share
bullish
•
TxCell SA
•
09 Oct 2017 23:12
•
Issuer-paid
Humanised CAR Tregs are a key step forward
TxCell has announced it has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A...
Edison Investment Research
Follow
52 Views
Share
bullish
•
TxCell SA
•
11 Jul 2017 22:22
•
Issuer-paid
Getting production in order
TxCell has agreed an important manufacturing supply contract with Lentigen, a German-US producer of the critical lentivirus reagent essential for...
Edison Investment Research
Follow
42 Views
Share
bullish
•
TxCell SA
•
14 Mar 2017 20:10
•
Issuer-paid
Aiming for first CAR Treg
TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform continues to develop well. TxCell has four indications in preclinical development...
Edison Investment Research
Follow
66 Views
Share
bullish
•
TxCell SA
•
28 Feb 2017 18:33
•
Issuer-paid
Exciting CAR opportunities; multiple indications
TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to...
Edison Investment Research
Follow
44 Views
Share
1
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x